Nurix Therapeutics

Nurix Therapeutics

Founded in 2009 by 2004 Nobel Laureate Michael Rape and colleagues from UC Berkeley, Nurix Therapeutics operates as a drug discovery and development company focused on the ubiquitin-proteasome system. Sands, who previously co-founded biotech firm Lexicon Pharmaceuticals, has served as CEO since 2014. The company's foundational science centers on DELigase, a DNA-encoded library platform designed to identify small molecules that either promote or inhibit ubiquitin-dependent protein degradation. This dual mechanism — degradation and ligase inhibition — differentiates its approach from earlier PROTAC-focused companies. Nurix targets proteins that traditional occupancy-driven inhibitors cannot reach, operating across oncology and immunology. The company's wholly owned oral BTK degrader, NX-5948, entered Phase 1b trials in 2024 for relapsed/refractory B-cell malignancies, following initial clinical data reported at the 2023 American Society of Hematology meeting. A second oral degrader, NX-2127, targets BTK with an added immunomodulatory cereblon-binding function. Outside oncology, the pipeline includes NX-0479, a CBL-B inhibitor designed to enhance antitumor immunity, and the company disclosed a Phase 1a initiation for NX-1607, an oral CBL-B inhibitor, in June 2024 focused on advanced solid tumors. Geographically, the firm operates from its headquarters in San Francisco's Mission Bay, extending its early-stage clinical operations to trial sites in both the United States and the United Kingdom. Since its $209 million initial public offering on Nasdaq in July 2020, Nurix has leveraged strategic partnerships to fund its platform without diluting equity in its most advanced clinical assets. A 2023 expansion of a collaboration with Seagen (now part of Pfizer) focused on an antibody-drug conjugate target. The company also maintains longstanding partnerships with Sanofi and Gilead Sciences. Sanofi, in a 2019 deal valued at up to $2.5 billion in milestones, secured rights to ligase inhibitors aimed at oncology and inflammatory diseases. In May 2024, Nurix presented preclinical data for its degrader-antibody conjugate platform at the American Association for Cancer Research meeting, signaling intent to pair its protein-degradation payloads with tumor-targeting antibodies for greater therapeutic precision. Nurix occupies a structurally distinct niche within biotech: it is a publicly traded, clinical-stage platform company competing aggressively in targeted protein degradation without depending on a single parent molecule or venture-style multi-asset rollup. Its governance reflects classic biotech independence, with Sands as both CEO and a board member alongside venture and institutional backers, though no individual family office controls strategy. This contrasts with private, founder-controlled biotech platforms that often manage heavily diversified portfolios of unrelated assets — here, the scientific thesis is singular, and the pipeline progression is gated by clinical data, not capital-deployment pressure.